Search
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Bromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. … Ethanolamine antihistamines produce marked sedation in most patients.
Synonyms: 2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamineAzlocillin
go.drugbank.com/drugs/DB01061ApprovedAzlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalTipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Rhodamine B
go.drugbank.com/drugs/DB16853ExperimentalCategories: Compounds used in a research, industrial, or household settingLimaprost
go.drugbank.com/drugs/DB09211InvestigationalIt also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function. … In 2011, Ono and DSP initiated Phase II clinical trials in Japan for the treatment of carpal tunnel syndrome. In 2013, these trials were discontinued because the study failed to demonstrate efficacy.
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this
Tertomotide
go.drugbank.com/drugs/DB12747InvestigationalTertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). … It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.